Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine mesothelioma animal model.Mesothelioma is a rare and aggressive cancer that develops in the thin tissue lining the lungs, abdomen, heart or testicles, strongly lin ...